American Century Companies Inc. raised its holdings in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 2.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,461 shares of the biotechnology company’s stock after acquiring an additional 3,088 shares during the quarter. American Century Companies Inc. owned about 0.20% of Repligen worth $18,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Fortis Capital Advisors LLC purchased a new position in shares of Repligen in the fourth quarter valued at $35,000. Clearstead Advisors LLC bought a new stake in shares of Repligen during the first quarter valued at about $38,000. Whittier Trust Co. lifted its holdings in shares of Repligen by 108.6% in the first quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock worth $41,000 after buying an additional 126 shares in the last quarter. Achmea Investment Management B.V. bought a new position in shares of Repligen in the fourth quarter valued at approximately $49,000. Finally, Covestor Ltd grew its stake in Repligen by 58.7% during the first quarter. Covestor Ltd now owns 484 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 179 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Repligen Stock Performance
RGEN stock opened at $173.91 on Friday. The company has a market capitalization of $9.70 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 3.78 and a beta of 1.01. Repligen Co. has a one year low of $134.64 and a one year high of $235.06. The company’s 50 day moving average price is $160.63 and its two-hundred day moving average price is $165.09.
Wall Street Analysts Forecast Growth
RGEN has been the topic of several recent analyst reports. StockNews.com started coverage on shares of Repligen in a research note on Thursday, August 17th. They issued a “sell” rating on the stock. Stephens lifted their price objective on Repligen from $180.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, August 3rd. Craig Hallum reduced their target price on Repligen from $207.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Stifel Nicolaus cut their price objective on Repligen from $210.00 to $200.00 in a report on Wednesday, June 28th. Finally, Royal Bank of Canada lifted their target price on shares of Repligen from $157.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.44.
Get Our Latest Analysis on RGEN
Insider Activity at Repligen
In other Repligen news, Director Karen A. Dawes sold 850 shares of Repligen stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $171.38, for a total value of $145,673.00. Following the transaction, the director now directly owns 83,741 shares of the company’s stock, valued at approximately $14,351,532.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.10% of the stock is currently owned by company insiders.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
- Five stocks we like better than Repligen
- The “How” and “Why” of Investing in 5G Stocks
- 3 Takeaways from the August Inflation Report
- What is a Stock Market Index and How Do You Use Them?
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- How to Invest in Small Cap Stocks
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
